Crystalline Cellulose Aggregates for Rapid Intranasal Drug Absorption
Solution Overview
Problem
Current intranasal compositions for opioid analgesic agents like morphine and antiemetic agents such as tropisetron face challenges with bioavailability due to first-pass metabolism, leading to adverse effects and delayed action, necessitating a rapid-acting, self-administrable, and convenient administration method that avoids gastrointestinal metabolism.
Innovation Solution
Development of powdery compositions for intranasal administration using crystalline cellulose aggregates with specific particle diameter ranges, which enhance the absorbability and rapid action of non-peptide/non-protein drugs, comparable to parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration is used for opioid analgesic agents, then the drug can be easily administered, but first-pass metabolism in the gastrointestinal tract and liver significantly decreases bioavailability and causes adverse effects
Solution Approach 1:
The nasal mucosa serves as an intermediary absorption pathway between the gastrointestinal tract and the bloodstream. By administering the drug through the nasal mucosa rather than orally, the drug avoids first-pass metabolism in the liver while maintaining ease of self-administration. The nasal mucosa acts as a mediator that enables direct absorption into the systemic circulation.
2Reliability
If intranasal administration is used to avoid first-pass metabolism, then bioavailability is improved, but the formulation must achieve both rapid action and high absorbability which is technically challenging
Solution Approach 1:
The patent changes the physical parameters of the drug formulation by controlling particle size (10-100 μm for rapid dissolution, 50-350 μm for sustained release) and using water-absorbing materials (hydroxypropyl cellulose, crystalline cellulose) to modulate drug release kinetics. These parameter changes enable the formulation to achieve both rapid action and high absorbability through controlled dissolution and absorption mechanisms.
Solution Approach 2:
The invention uses composite material systems combining water-absorbing materials (hydroxypropyl cellulose, crystalline cellulose) with the drug substance. This composite formulation leverages the water-absorbing properties of the carriers to control drug release and enhance absorption, achieving both rapid action and sustained release effects simultaneously.
3Ease of operation
If conventional intranasal compositions are used, then the administration is self-administrable and painless, but the drug action is delayed and bioavailability is reduced due to first-pass metabolism
Solution Approach 1:
The water-absorbing materials (hydroxypropyl cellulose, crystalline cellulose) are pre-positioned in the nasal formulation to facilitate rapid drug dissolution and absorption upon contact with nasal mucosa. This preliminary preparation of the formulation system enables immediate drug action without delay, while the self-administration capability is maintained through the simple nasal powder delivery method.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve high bioavailability and rapid drug concentration in blood, providing immediate relief for pain and nausea, with bioavailability comparable to subcutaneous and intravenous administration methods.
Implementation Method 1
the nasal mucosa has a well developed vascular network and is thus histologically advantageous for drug absorption
Implementation Method 2
a base that is water-absorbing and water-insoluble and has 90% (w/w) or more of particles with a diameter in the range of 10 to 100 μm
Implementation Method 3
a base that is water-absorbing and gel-forming and has 90% (w/w) or more of particles with a diameter in the range of 50 to 350 μm
Data Source
AI summary
Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.



